Innovative and naturally derived therapeutic products

CannPal Animal Therapeutics Limited (ASX: CP1) is a listed animal health company developing innovative and naturally derived plant-based therapeutic products for pets targeting the endocannabinoid system that owners can trust are both safe and scientifically validated.

The company has a research focus on cannabinoids, the active pharmaceutical ingredients extracted from the cannabis plant, to provide veterinarians and pet owners with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.

CannPal has identified a significant opportunity to benefit from the rapidly growing medical cannabis and animal health markets by developing innovative therapeutics that can influence the endocannabinoid system with full regulatory approval for veterinary distribution.

A unique investment opportunity in a growing market

CannPal Animal Therapeutics Limited (“CannPal”) is a pharmaceutical-focused animal health company researching the benefits of medical cannabis for companion animals. The company is listed on the Australian Stock Exchange (ASX) in 2017, trading under the ASX ticker “CP1”. CannPal was founded to research, develop and commercialise, regulatory approved medicines derived from the medical cannabis plant to provide veterinarians with clinically validated and standardised therapeutics to treat animals in a safe and ethical way.